Authors' response
- John Field1,
- David Baldwin2,
- Kate Brain3,
- Anand Devaraj4,
- Tim Eisen5,
- Stephen W Duffy6,
- David M Hansell7,
- Keith Kerr8,
- Richard Page9,
- Mahash Parmar10,
- David Weller11,
- David Whynes12,
- Paula Williamson13
- 1Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, London, UK
- 2City Campus, Nottingham University Hospitals, Nottingham, UK
- 3Institute of Medical Genetics, Cardiff University, Cardiff, UK
- 4Department of Radiology, St George's Hospital London, London, UK
- 5Department of Oncology, University of Cambridge, Cambridge, UK
- 6Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, London, UK
- 7Department of Radiology, Royal Brompton Hospital, London, UK
- 8Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, UK
- 9Department of Surgery, Liverpool Heart & Chest Hospital, Liverpool, UK
- 10Medical Statistics and Epidemiology, University College London, London, UK
- 11Clinical Sciences and Community Health, Division of Community Health Sciences, University of Edinburgh, Edinburgh, UK
- 12School of Economics, University of Nottingham, Nottingham, UK
- 13Department of Medical Statistics, University of Liverpool, Liverpool, UK
- Correspondence to Professor John Field, Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre, Roy Castle Building, 200 London Road, London L3 9TA, UK; j.k.field{at}liv.ac.uk
- Accepted 20 July 2011
- Published Online First 13 September 2011
- Pulmonary embolism
- aspergillus lung disease
- imaging/CT MRI
- sarcoidosis
- occupational lung disease
- interstitial fibrosis
- COPD epidemiology
- emphysema
- bronchiectasis
- bronchoscopy
- cystic fibrosis
- lung cancer
- COPD mechanisms
- asthma
- asthma mechanisms
- COPD exacerbations
- lung cancer
- cough/mechanisms/pharmacology
We thank Dr Young for his comments on the recent UKLS position statement.1 We are aware of the current studies on chronic obstructive pulmonary disease (COPD) and lung cancer. However, there is no validated lung cancer risk model in the UK which currently incorporates dynamic lung volumes that …
